UnityPoint Health - Des Moines

Melanoma Research Studies


S1320: A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib and Trametinib in BRAFV600E/K Mutant Melanoma

S1404: A Phase III Randomized Trial Comparing Physician / Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma